Compare Agilent Technologies Inc (A) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Goldman Sachs Group Inc — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Goldman Sachs Group Inc trades at $1,033.22 (market cap $301.22B). The key difference: Goldman Sachs Group Inc is far larger — about 7.2× Agilent Technologies Inc's market cap, and Goldman Sachs Group Inc pays the higher dividend (1.93%). Which is the better fit depends on your goals.
| A | GS | |
|---|---|---|
Market Cap | $42.00B | $301.22B |
Sector | Health | Financials |
52-Week High | $157.20 | $1.15K |
52-Week Low | $110.24 | $715.95 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | 1.93% |
Volume | — | 2,592,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Goldman Sachs (GS) trades at $1,034.41, down 0.5% on the day, with a neutral technical signal. The company shows strong fundamental momentum with three consecutive quarterly EPS beats and revenue growth accelerating to $58.3B in 2025. Analyst consensus is mixed with 40% buy ratings but a $1,160 price target suggesting 12% upside potential. Recent news highlights Goldman's leadership role in major upcoming IPOs including Anthropic, SpaceX, and OpenAI.
The outlook remains positive given Goldman's positioning in the upcoming AI IPO wave and strong investment banking pipeline. Key risks include volatile cash flow patterns with negative operating cash flow in recent periods and market sensitivity to interest rate changes. The stock appears reasonably valued at 16x P/E with 31.7% net margins supporting further upside if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
